title: In vivo effects of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF), alone and associated with zidovudine, on HIV-1 replication.
abstract: The effects of the administration of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) on HIV-1 replication were evaluated in 15 patients with advanced HIV-1 disease and severe leukopenia, by monitoring immunocomplex dissociated p24 antigenemia, during 21 overall courses of therapy with rHuGM-CSF (lasting 2 to 27 weeks), alone or associated with zidovudine. During most treatment courses with rHuGM-CSF (17 out of 21), no significant modifications of HIV-1 antigenemia were recognized. A remarkable increase in viral replication occurred in only two courses out of 13 performed with rHuGM-CSF alone, while a significant reduction of antigenemia was observed in two courses of rHuGM-CSF out of 8 administered with zidovudine, after 10 weeks of combined treatment. Our experience is discussed on the grounds of both experimental and clinical investigations dealing with interactions between rHuGM-CSF and zidovudine during HIV-1 disease, focusing on risks of increased viral burden during treatment with rHuGM-CSF alone, and the synergistic activity of the combination with zidovudine against HIV-1 replication.
authors.affiliation: Department of Clinical and Experimental Medicine, University of Bologna, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Manfredi
authors.forename: M C
authors.initials: MC
authors.lastname: Re
authors.forename: G
authors.initials: G
authors.lastname: Furlini
authors.forename: R
authors.initials: R
authors.lastname: Gorini
authors.forename: F
authors.initials: F
authors.lastname: Chiodo
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000821:virology; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D016655:HIV Core Protein p24 / Q000097:blood / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy / Q000821:virology; D011994:Recombinant Proteins; D014779:Virus Replication / Q000187:drug effects*; D015215:Zidovudine / Q000008:administration & dosage*
chemical_list: D016655:HIV Core Protein p24; D011994:Recombinant Proteins; D015215:Zidovudine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor